Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab After Chemo-Radiotherapy in Stage II-IV MSS Rectal Cancer
NCT03102047Phase 2Completed
- Sponsor
- NSABP Foundation
- Start
- May 2018
- Primary completion
- Feb 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in rectal cancer, sponsored by NSABP Foundation. Primary endpoint: Median modified Neoadjuvant Rectal Score at 12 weeks. Started May 2018; status: completed.
02
Drugs
durvalumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT03102047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03102047.